Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Clarksterh	10/20/2004 8:12:05 AM
	of 1386

Doing some research on potential off-label uses of DEX: 1) Spinal cord injury. A very good bet that if DEX works in TBI it will work in Spinal Cord Injury. However, from a revenue point of view it isn't a huge market - somewhere near 10,000 patients per year in the US. 2) Penetrating TBI. So far I have had a hard time figuring out the incidence of penetrating vs non-penetrating. People publishing numbers are somewhat vague about the numbers in each category. The best numbers I can find are only for overall TBI incidence of 1.5M cases of TBI per year as per CDC and there seems to be an assumption that the significant majority of those are non-penetrating. And the penetrating injuries are much more quickly fatal. But I am still looking for some hard numbers. Clark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next